Niacinamide Doesn't Stop Melanin Production — It Hijacks the Delivery System

Niacinamide is one of the most widely used ingredients in skincare. It appears in serums, moisturisers, eye creams, and virtually every product that claims to improve skin tone. Most people who use it believe it reduces melanin production — that it tells your skin to make less pigment.

It does not do that.

Niacinamide does not inhibit tyrosinase. It does not modulate MITF. It does not interfere with the cellular machinery that synthesises melanin. Your melanocytes keep producing pigment at the same rate whether niacinamide is present or not.

What niacinamide does is intercept the delivery. And that distinction matters far more than most people realise.

The melanin delivery system most people don't know about

Melanin is manufactured inside melanocytes — specialised cells that sit in the basal layer of your epidermis. But melanocytes are not the cells that determine your visible skin tone. Melanin only becomes visible when it reaches keratinocytes, the cells that make up the surface layers of your skin.

The mechanism that moves melanin from one cell type to the other is melanosome transfer. Melanosomes are the organelles where melanin is synthesised and stored. Once they are mature, the melanocyte extends projections called dendrites toward surrounding keratinocytes — each melanocyte services roughly thirty-six keratinocytes — and physically delivers packages of melanin to each one.

This is why pigmentation is not simply a question of how much melanin your skin produces. It is also a question of how efficiently that melanin is distributed across the cells that people actually see.

What niacinamide actually does

In 2002, Hakozaki and colleagues published a study in the British Journal of Dermatology that changed how dermatological researchers understood niacinamide's role in pigmentation. Using a co-culture model of melanocytes and keratinocytes, they demonstrated that niacinamide reduced melanosome transfer by 35 to 68 per cent — without affecting melanin synthesis itself.

The melanocytes kept producing pigment. The melanosomes kept maturing. But the delivery step — the physical handoff from melanocyte to keratinocyte — was significantly inhibited.

Think of it this way. Most brightening ingredients work inside the factory, trying to slow down the production line. Niacinamide leaves the factory alone. It parks itself on the loading dock and blocks the delivery trucks from leaving.

The pigment still exists. It simply doesn't reach the surface in the same quantity. Over time, as keratinocytes at the surface naturally shed through the skin's turnover cycle, the visible pigmentation fades — not because less melanin was made, but because less melanin was delivered.

Why this mechanism is clinically significant

The reason this distinction matters is not academic. It has real implications for how pigmentation should be treated.

Most brightening ingredients target a single point in the pigmentation pathway — typically tyrosinase inhibition. Tyrosinase is the enzyme that catalyses the first committed step of melanin synthesis, and inhibiting it is an effective strategy. Oligopeptide-68 goes even further upstream, modulating MITF — the master transcription factor that controls whether the cell produces tyrosinase in the first place.

But neither of these addresses what happens after melanin has already been made. If melanosomes have already formed and are ready for transfer, an ingredient that only targets production has arrived too late for that batch of pigment. It will still reach the surface.

This is why niacinamide occupies a unique and often underappreciated position in the pigmentation pathway. It acts at a stage that no tyrosinase inhibitor — however potent — can reach. It handles the melanin that has already been manufactured but not yet delivered.

The case for multi-stage intervention

If you have been following our recent articles on pigmentation science, this connects to a principle Dr Alison Jamieson built into the formulation logic of the Brightening Serum: the most effective approach to pigmentation is not a single powerful ingredient. It is a system that intervenes at multiple stages of the pathway simultaneously.

The Aliangé Brightening Serum contains Oligopeptide-68 to modulate the upstream signal — fewer production orders issued. It contains niacinamide to intercept melanosome transfer — less pigment delivered to the surface. And it contains a calibrated blend of alpha-hydroxy acids — lactic, glycolic, malic, tartaric, and citric — to accelerate the turnover of keratinocytes that have already received melanin, moving them off the surface faster.

Three intervention points. Three different mechanisms. One coherent system.

This is not an ingredient list assembled for marketing claims. It is a formulation built around the biology of how pigmentation actually works — from the initial signal to produce melanin, through its manufacture and delivery, to the turnover of the cells that carry it.

Where niacinamide fits beyond brightening

Niacinamide's role in the Aliangé protocol extends beyond pigmentation. It is the namesake active in Biocinamide, where it serves a different function entirely — supporting ceramide synthesis and strengthening the skin's barrier. It also appears in the Rejuvenating Eye Cream, where it contributes to tone evening in the periorbital area.

The ingredient's versatility is well documented. Beyond melanosome transfer inhibition, niacinamide has evidence supporting its role in reducing transepidermal water loss, improving lipid barrier function, and modulating inflammatory pathways. Dr Alison Jamieson — MBBS, FRACGP, Dip Derm — selected it not for one function, but because it supports multiple aspects of skin health across several products in the protocol.

This is the difference between using niacinamide because it appears on trending ingredient lists, and using it because you understand the specific biological step it addresses — and you have placed it alongside ingredients that handle the steps it cannot.

What this means for your approach to pigmentation

If you are using a single-ingredient brightening product, it is likely addressing only one stage of the pigmentation process. That stage might be production, or it might be delivery, or it might be turnover. But pigmentation is not a single-stage problem.

The reason many people feel their brightening products plateau — producing initial improvement that then stalls — is often that they are treating one stage effectively while the others continue unchecked. Melanin keeps being produced, or keeps being delivered, or keeps accumulating in surface cells that are not turning over fast enough.

A protocol that addresses melanin production, melanosome transfer, and keratinocyte turnover simultaneously is not doing three jobs to be thorough. It is doing three jobs because the biology requires it.

This article discusses ingredient mechanisms supported by published research. Individual results vary. The Aliangé Brightening Serum is formulated to support the appearance of a more even skin tone as part of a complete protocol. If you are managing persistent or complex pigmentation, Dr Alison Jamieson recommends professional assessment alongside any at-home protocol. Take our 60-second skin quiz to find the protocol indicated for your concern.

Internal links: - Brightening Serum PDP - Biocinamide PDP - Rejuvenating Eye Cream PDP - Skin Quiz - Previous: Hydroquinone Is Not the Only Effective Brightener - Previous: Oligopeptide-68 Outperformed Hydroquinone in a Clinical Trial